- Home
- FRA vs CSTL Comparison
FRA vs CSTL Comparison
Compare FRA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRA
- CSTL
- Stock Information
- Founded
- FRA 2003
- CSTL 2007
- Country
- FRA United States
- CSTL United States
- Employees
- FRA N/A
- CSTL N/A
- Industry
- FRA Investment Bankers/Brokers/Service
- CSTL Medical Specialities
- Sector
- FRA Finance
- CSTL Health Care
- Exchange
- FRA Nasdaq
- CSTL Nasdaq
- Market Cap
- FRA 466.7M
- CSTL 555.8M
- IPO Year
- FRA N/A
- CSTL 2019
- Fundamental
- Price
- FRA $13.38
- CSTL $23.46
- Analyst Decision
- FRA
- CSTL Strong Buy
- Analyst Count
- FRA 0
- CSTL 6
- Target Price
- FRA N/A
- CSTL $37.67
- AVG Volume (30 Days)
- FRA 165.4K
- CSTL 725.3K
- Earning Date
- FRA 01-01-0001
- CSTL 08-04-2025
- Dividend Yield
- FRA 11.06%
- CSTL N/A
- EPS Growth
- FRA N/A
- CSTL N/A
- EPS
- FRA N/A
- CSTL N/A
- Revenue
- FRA N/A
- CSTL $346,269,000.00
- Revenue This Year
- FRA N/A
- CSTL N/A
- Revenue Next Year
- FRA N/A
- CSTL N/A
- P/E Ratio
- FRA N/A
- CSTL N/A
- Revenue Growth
- FRA N/A
- CSTL 20.40
- 52 Week Low
- FRA $11.33
- CSTL $14.59
- 52 Week High
- FRA $13.10
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- FRA 66.52
- CSTL 74.17
- Support Level
- FRA $13.20
- CSTL $20.35
- Resistance Level
- FRA $13.27
- CSTL $20.80
- Average True Range (ATR)
- FRA 0.06
- CSTL 0.90
- MACD
- FRA 0.01
- CSTL 0.36
- Stochastic Oscillator
- FRA 99.15
- CSTL 95.14
About FRA Blackrock Floating Rate Income Strategies Fund Inc
Blackrock Floating Rate Inc Stra Fd Inc is a United States-based diversified closed-ended management investment company. The Fund's investment objective is to provide shareholders with high current income and preservation of capital with investment in a diversified, leveraged portfolio consisting of floating-rate debt securities and instruments.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.